Drug Trial Radar · NCT06825702
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
May 1, 2025
Primary completion
Nov 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Kiora Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open label study to assess the safety, tolerability, and efficacy of KIO-104 administered by IVT injection to the study eye of eligible participants with macular edema.
Conditions
- Macular Edema
Interventions
KIO-104Drug
KIO-104 is an ophthalmic formulation for IVT injection of the active pharmaceutical ingredient (API) KIO-100, a novel, non-steroidal, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 23months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Sydney Eye Hospital
Sydney, New South Wales, Australia · Recruiting
Sydney West Retina
Westmead, New South Wales, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Hobart Eye Surgeons
Hobart, Tasmania, Australia · Recruiting
Centre for Eye Research Australia
East Melbourne, Victoria, Australia · Recruiting
Lions Eye Institute Limited
Nedlands, Western Australia, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.